Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Objective and methodTo estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high-burden, antimony-resistant area of Northern Bihar, India.ResultsParomomycin is the cheapest option ($7450 to treat 1000 patients). Treating 1000 patients with oral miltefosine would cost $119,250 at the current private market price or $64,383-$75,129 at preferential public sector price depending on the size of the order. With AmBisome it would be $163,600 or $229,500 depending on the dose (10 or 15 mg/kg total). These costs are without considering other direct costs (daily intramuscular injections for 3 weeks for paromomycin; intravenous devices and hospitalization for AmBisome; directly observed treatment if applied for miltefosine) and indirect costs.ConclusionThese calculations provide useful basic information for projections.

Original publication




Journal article


Tropical medicine & international health : TM & IH

Publication Date





88 - 92


UNICEF/UNDP/WB/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland.


Humans, Leishmaniasis, Visceral, Body Weight, Phosphorylcholine, Amphotericin B, Paromomycin, Liposomes, Antiprotozoal Agents, Anthropometry, Age Distribution, Sex Distribution, Dose-Response Relationship, Drug, Adolescent, Adult, Aged, Middle Aged, Child, Child, Preschool, Infant, Drug Costs, India, Female, Male